Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus MACROTEC.
CERETEC vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Not applicable for diagnostic use.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical